British biopharma start-up Mereo to list in London - (London South East via NewsPoints Desk)

  • Mereo BioPharma, which is testing three drugs developed by Novartis, indicated that it would list on London's junior AIM market to raise capital to develop its drugs, as reported in London South East.

  • According to the news source, Mereo wants to acquire drugs discovered by large pharmaceutical companies, as well as fund and design later-stage studies.

  • CEO Denise Scots-Knight said the funding would help advance the clinical development of its experimental drugs for brittle bone syndrome, acute chronic obstructive pulmonary disease and hypogonadotropic hypogonadism in obese men.

  • "Our strategy is to build, over time, a diverse portfolio, and having publicly traded shares will provide additional flexibility to secure the next product candidates, which are likely to be primarily sourced from large pharmaceutical companies," she said.

To read more NewsPoints articles, click here.

Reference Articles